However, when we compared the different therapeutic approaches for T‐ALL, TNFAIP3 mutation significantly predicted poor OS for adult T‐ALL patients treated with chemotherapy, but it was not associated with OS for patients treated with HSCT; thus, it is thought that HSCT could overcome these poor genetic alterations. This evidence concerns the gene TNFAIP3 and acute lymphoblastic leukemia.